Ariana analysis tech improves trial design

Previous trial data, mined properly, provides a tool for fine-tuning follow-on trial design. The devil, of course, is in the details. But by combining decision-support technology with statistical analysis software, Ariana Pharma has developed the means to consider combinations of subject characteristics to discern those who might benefit most from a treatment.

Ariana Pharma uses the KEM Clinicals decision-support platform in conjunction with statistical analysis software like SAS, according to eCliniqua. The combination allows for hypothesis testing via trial data on subject response to individual parameters, allowing researchers to discern treatment indications early in drug development.

KEM, for Knowledge Extraction and Management, helps researchers study consumer behavior and detect safety issues in non-pharma industries; its use is relatively new in clinical trials. Ariana says it is working with about 20 big-pharma companies now and small biotechs are beginning to show interest.

- see the article
- here's our earlier KEM coverage

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.